Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.